---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-035625"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:43:44.217906+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mira Pharma selects neuropathic pain for Ketamir-2, submits pre-IND request to FDA

## Summary
- Selected neuropathic pain as primary indication for oral ketamine analog Ketamir-2.
- Submitted pre-IND meeting request to FDA; meeting expected October 2024.
- Plans to begin human trials in Q1 2025 following IND submission.
- No financial details or trial data disclosed in this filing.

## SEC filing metadata
- accession: 0001493152-24-035625
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224035625/0001493152-24-035625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224035625/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-035625
- JSON: https://secwatch.observer/filing/0001493152-24-035625.json
- Plain text: https://secwatch.observer/filing/0001493152-24-035625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.